Expression of cyclo‐oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor β1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine

No abstract is available for this paper.

• Publication year

  2006

• Venue

  British Journal of Surgery

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/bjs.5426PMID 17022010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.

  2004cited by this paper
• Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

  2004cited by this paper
• Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2.

  2004cited by this paper
• Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-i

  2004cited by this paper
• Cyclooxygenase-2 Induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C Up-Regulation

  2004cited by this paper
• Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.

  2004cited by this paper
• Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

  2004cited by this paper
• Transforming Growth Factor-β (TGF-β) Activates Cytosolic Phospholipase A2α (cPLA2α)-mediated Prostaglandin E2 (PGE)2/EP1 and Peroxisome Proliferator-activated Receptor-γ (PPAR-γ)/Smad Signaling Pathways in Human Liver Cancer Cells

  2004cited by this paper
• Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells.

  2004cited by this paper
• COX-2 inhibition in upper aerodigestive tract tumors.

  2004cited by this paper
• Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

  2003cited by this paper
• COX-2 and angiogenesis in gastric cancer.

  2003cited by this paper
• Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.

  2003cited by this paper
• A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.

  2003cited by this paper
• Cellular Prostaglandin E2 Production by Membrane-bound Prostaglandin E Synthase-2 via Both Cyclooxygenases-1 and -2*

  2003cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

  2002cited by this paper
• The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.

  2002cited by this paper
• Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.

  2002cited by this paper
• A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

  2002cited by this paper
• Angiogenesis inhibition in solid tumors.

  2001cited by this paper
• Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.

  2001cited by this paper
• Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.

  2001cited by this paper
• Differential expression of transforming growth factors-β1, -β2 and -β3 in human colon carcinoma

  2001cited by this paper
• Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.

  2001cited by this paper
• Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma.

  2001cited by this paper
• Role of transforming growth factor-beta signaling in cancer.

  2000cited by this paper
• Role of Transforming Growth Factor-β Signaling in Cancer

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.

  2000cited by this paper
• Pathology and genetics: Tumours of the digestive system

  2000cited by this paper
• Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.

  2000cited by this paper
• The role of cyclooxygenases in inflammation, cancer, and development

  1999cited by this paper
• Cyclooxygenase-2 expression in human esophageal carcinoma.

  1999cited by this paper
• Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma

  1999cited by this paper
• The epidemiology of cancer of the small bowel.

  1998cited by this paper
• Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.

  1998cited by this paper
• Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

  1998cited by this paper
• Expression of cyclooxygenase-2 in human gastric carcinoma.

  1997cited by this paper
• Differential localization of transforming growth factor‐β isoforms in human gastric mucosa and overexpression in gastric carcinoma

  1997cited by this paper
• Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• Therapeutic Role of Cyclooxygenase-1 (COX-1) Inhibition, Challenging the Conventional View of COX-1 as Purely Constitutive.

  2026cites this paper
• Case Report: A case of advanced duodenal adenocarcinoma in complete remission after chemotherapy combined with targeted therapy and radiotherapy

  2022cites this paper
• Eicosanoids in carcinogenesis

  2019cites this paper
• Precancerous niche (PCN), a product of fibrosis with remodeling by incessant chronic inflammation

  2019cites this paper
• Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature

  2018cites this paper
• Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single‐center, open‐label, phase 2 study

  2017cites this paper
• Antiangiogenic potential of grape stem extract through inhibition of vascular endothelial growth factor expression.

  2014cites this paper
• Tumor and Stem Cell Biology SIX1 Promotes Tumor Lymphangiogenesis by Coordinating TGFb Signals That Increase Expression of VEGF-C

  2014cites this paper
• Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer.

  2014cites this paper
• SIX1 promotes tumor lymphangiogenesis by coordinating TGFβ signals that increase expression of VEGF-C.

  2014cites this paper
• Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.

  2013cites this paper
• Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial

  2013cites this paper
• Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

  2013cites this paper
• Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications

  2011cites this paper
• Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients

  2011cites this paper
• Differential expression of cyclooxygenases in hypertrophic scar and keloid tissues

  2009cites this paper
• Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

  2009cites this paper
• Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review.

  2009cites this paper
• Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer.

  2008cites this paper
• Gene Expression Studies Demonstrate that the K-ras/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors

  2008cites this paper
• Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix.

  2007cites this paper